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ABSTRACT 
Purpose of review 
Gadolinium-enhancement depicts BBB disruption associated with new inflammatory MRI lesions in 
MS and is widely used for diagnosis and therapeutic monitoring. However, earlier and more specific 
markers of inflammation are urgently needed.  
Recent findings 
Susceptibility Weighted Images demonstrate the importance of the central vein in the formation of 
MS lesions. Perfusion weighted imaging techniques can show focal and diffuse low-grade 
inflammatory changes not visible on conventional MRI. Leptomeningeal enhancement could be part 
of the etiology of subpial cortical MS lesions. Ultra-small Superparamagnetic Particles of Iron Oxide 
can identify neuroinflammatory changes in addition to gadolinium enhancement and as such identify 
different types and phases of MS lesions. TSPO PET-tracers identify activated microglia and an 
increase in TSPO uptake in both MS lesions and normal appearing brain tissue is related to disease 
severity and progression. A range of novel tracers for microglia activation are under development as 
well as radioligands that can label therapeutic drugs. 
Summary 
Novel MRI and PET techniques improve in vivo visualization and quantification of the pleomorphic 
aspects of neuroinflammation, providing us with a unique insight in its pathogenesis, clinical 
relevance and therapy responsiveness in MS. 
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 KEYPOINTS 
 Neuroinflammation in multiple sclerosis is a heterogeneous process that is inadequately 
visualized by conventional MRI. 
 Novel MRI techniques such as Susceptibility Weighted Imaging and Perfusion Weighted 
Imaging provide us with new insights in the development of MS lesions and low-grade 
neuroinflammation. 
 Novel contrast agent USPIO and new uses for traditional gadolinium based contrast agents 
identify different aspects of this pleomorphic process. 
 TSPO PET shows that increased microglia activation is present in both normal appearing 
tissue and MS specific lesions and is related to disease severity and progression 
 A wide range of novel PET markers will give us unique insights in the pathophysiology of MS 
and the pharmacokinetics of drugs used in this disease. 
 
 
 
  
INTRODUCTION 
Multiple sclerosis (MS) is a complex immune-mediated disorder of the brain and spinal cord 
characterized by neuroinflammation, demyelination, gliosis, axonal degeneration and neuronal loss. 
During the past decades imaging techniques such as magnetic resonance imaging (MRI) have 
contributed considerably to the improvement of clinical decision making and the design of clinical 
trials in multiple sclerosis. Additionally, a range of novel tools using advanced MRI or positron 
emission tomography (PET) technologies have been emerging from which we can obtain unique 
insights into pathogenesis of MS. The present article will summarize current developments in MRI 
and PET techniques to depict neuroinflammation in MS.  
 
 
MAGNETIC RESONANCE IMAGING 
Conventional MRI techniques, such as T2- and T1-weighted sequences, are generally used in the 
diagnosis, follow-up and therapeutic consideration in individual MS patients and clinical trials. 
Currently the most commonly used MRI marker for acute inflammation is gadolinium enhancing 
white matter lesions (WML), indicating disrupted blood-brain barrier (BBB) in these active MS 
lesions.  Gadolinium-based contrast agents (GBCA) are generally considered safe in patients without 
severe renal insufficiency, but there is a potential risk for anaphylactoid-type reactions.[1] Moreover, 
recent studies suggest accumulation of (potentially toxic) gadolinium may occur in brain tissue in the 
absence of any significant renal dysfunction.[2*,3,4] Apart from the potential side effects of GBCA, 
the correlation between conventional MRI markers for neuroinflammation and the clinical 
manifestations of MS in an individual patient is modest. Histopathological studies have shown that 
(inflammatory) brain pathology in MS is much more diverse and widespread than identified with 
conventional MRI techniques alone. Various developments regarding in vivo MR imaging have 
advanced our understanding of the pleomorphic aspects of neuroinflammation in MS in recent years. 
  
SUSCEPTIBILITY WEIGHTED IMAGES 
The magnetic property of brain tissue is largely determined by the presence of paramagnetic iron, 
oxygen levels of the blood in capillaries and veins and the amount of diamagnetic myelin and tissue 
water. Susceptibility Weighted Images (SWI) uses the differences in magnetic susceptibility in brain 
tissue to identify MS-related tissue changes such as iron deposition, myelin density and venous 
capillary network density. To provide a quantitative measure for susceptibility Quantitative 
Susceptibility Mapping (QSM) was developed. However, these techniques cannot disentangle the 
different and sometimes opposing factors that increase or decrease tissue susceptibility.[5] 
Considering the pathophysiology of neuroinflammatory lesions in MS, one of the most striking results 
from SWI studies is the identification of the central vein in lesions development. Such a central vein 
has been demonstrated in both periventricular and subcortical MS lesions  and is significantly less 
frequent in non-MS WMLs.[6–8] Moreover, in a longitudinal 7 Tesla study by Dal-Bianco et al., an 
increase in volume of central veins of MS lesions was seen in the development of such a lesions.[9*] 
This underlines the primal role of the central vein in lesion formation. In agreement with this, a 
recent retrospective 3T and 7T MRI study by Absinta et al. demonstrated subtle signal changes on T2-
FLAIR and T2* images up to 2 months before onset of focal gadolinium enhancing WML, that co-
localize with the developing lesion’s central vein.[10*] Finally, SWI images can depict areas with 
phase shift without signal increase in other sequences, which may reflect areas of microglia 
activation (pre-active lesions).[11] 
  
PERFUSION-WEIGHTED IMAGING 
Perfusion MRI is a collective term for three MR techniques that measure changes in cerebral 
hemodynamics. Dynamic contrast-enhanced (DCE) MRI measures the integrity of the BBB using GBCA 
as an in vivo marker of low-grade neuroinflammation. Increased permeability of the BBB due to 
neuroinflammation enables extravasation of GBCA and the extravascular accumulation of such 
contrast agents increases the signal intensity in T1-weighted MRI images. By repeated acquisition of 
T1-weighted images during infusion of GBCA, DCE-MRI reveals tissue properties at a microvascular 
level, providing quantitative information on BBB integrity and leakage space as measures of (low-
grade) neuroinflammation within and outside visible lesions.[12**,13]  
Dynamic susceptibility contrast-enhanced (DSC) MRI measures cerebral blood volume and flow by 
monitoring the first pass of a bolus of GBCA by a series of T2*-weighted MRI images. Regional 
decreased in blood volume (CBV) and flow (CBF) have been reported in different stages of 
MS.[14,15*,16]  
In contrast to the previous two methods, arterial spin labeling (ASL) is a non-invasive perfusion 
technique that uses magnetization of blood as an endogenous contrast agent.[17*,18,19] In an ASL 
study using multiple delay times, an increase in bolus arrival time (BAT) was demonstrated,  
indicating reduced perfusion. This is suggested to be caused by widespread arteriolar vasodilation 
associated with neuroinflammation.[17*] 
 
In various recent studies both an increase and a decrease in cerebral perfusion have been linked to 
neuro-inflammatory changes in MS and clinically isolated syndrome 
(CIS).[12**,13,14,15*,16,17*,18,19] Those contradictory results might imply changes in perfusion 
occur during inflammation. Standardization of acquisition techniques and post-processing methods 
could help further implementation of perfusion-weighted MRI. 
 
LEPTOMENINGEAL ENHANCEMENT 
Besides the parenchymal  GBCA enhancement used in the diagnoses and therapeutic decision 
making in MS, leptomeningeal enhancement has been described as part of the pathophysiology of 
MS (Figure 1).[20] Similar to the process in lesions, gadolinium enhancement of the leptomeninges is 
a result of vascular leakage and an indirect measure of leptomeningeal inflammation.  Traditionally 
leptomeningeal enhancement is considered suggestive of diagnoses other than MS (e.g. sarcoid), but 
pathological studies have associated such leptomeningeal inflammation with subpial cortical 
demyelination and neurodegeneration in both early and late phases of MS.[21,22] In the last year, 
two MRI studies have aimed to quantify the prevalence and distribution of leptomeningeal 
inflammation in MS using 3 Tesla post-contrast T2-weighted fluid-attenuated inversion recovery (T2-
FLAIR) MRI.[23**,24*] Absinta et al. reported focal, usually perivascular, leptomeningeal 
enhancement in 74 of 299 MS patients and in one of 37 neurologically healthy controls.[23**] 
Strikingly, this prevalence was nearly twice as frequent in progressive MS patients (33%) compared 
to relapsing remitting MS (RRMS) (19%). In two cases that came to autopsy and pathologic 
evaluation confirmed the presence of perivascular leptomeningeal inflammation in three foci that 
enhanced in vivo, all in close relation to confluent cortical demyelination. On the contrary, Eisele et 
al. reported only one single case of focal leptomeningeal enhancement in a cohort of 122 MS 
patients of which only 15 had progressive MS.F[24*] As a positive control group, 5 patients with 
stroke where included, all of whom showed leptomeningeal enhancement in a diffuse pattern. The 
conspicuous difference in prevalence between both studies could be attributed to the differences in 
patient population or in scanning techniques. This argues for further studies to determine the actual 
prevalence, natural history and clinical relevance of focal leptomeningeal enhancement in MS and its 
relation to cortical lesion formation. 
 
ULTRASMALL SUPERPARAMAGNETIC PARTICLES OF IRON OXIDE 
As mentioned before, gadolinium-enhancement indicates a defective BBB and is therefore an 
indirect measure of neuroinflammation in MS. In these lesions infiltrating blood-born monocytes play 
a crucial role, causing myelin breakdown and phagocytosing myelin debris. The phagocytic infiltration 
in the CNS can be directly detected in vivo with the use of Ultra-small Superparamagnetic Particles of 
Iron Oxide (USPIO) as an MRI contrast agent. Several hours after intravenous administration of USPIO 
these small nanoparticles are captured by phagocytic monocytes and accumulate in these cells.[25] 
Their iron oxide core distorts the magnetic field, causing a rapid decreases in T1- and T2-relaxation 
times of water molecules, resulting in an increased signal intensity on T1-weighted images and a 
decrease of signal on T2-weighted-gradient echo images.[25,26] Areas of altered intensity on delayed 
MRI scans presumably reflect the infiltration of USPIO-loaded macrophages in active MS lesions. 
USPIO enhancement can have one of three patterns:  focal, ring-like or “return-to-isointensity” (after 
having been hypointense on native T1-weighted images).[27] Furthermore, global changes in the T1 
signal in normal appearing brain tissue can demonstrate subtle generalized inflammatory activity 
without apparent BBB damage.[28]  
Clinical pilot trials have demonstrated that the use of both GBCA and USPIO in MS patients identifies 
more inflammatory lesions than gadolinium alone, range from a 4% to 244% increase.[27,29,30] The 
subgroup of lesions that enhanced with both contrast agents were characterized by a more severe 
evolution.[27,30] 
A recent study by Maarouf et al. in 18 CIS patients showed that USPIO enhancing lesions are already 
present at the onset of MS, but to a lesser extent than previously reported in RRMS patients.[31*]  
The presence of such lesions was associated with more severe and persistent local tissue injury after 
12 months of follow-up, but not with changes in Expanded Disability Status Scale (EDSS). 
These limited number of studies show that USPIO allow for measurement of inflammation not 
possible with other MRI contrast agents, but the lack of available contrast-agents limits further 
development. 
 
 
POSITRON EMISSION TOMOGRAPHY 
PET is a noninvasive molecular imaging technique to quantify biochemical and physiological 
processes in vivo. It measures the bio-distribution of a radioligand or tracer, a radioactive isotope 
bound to biologically active molecule.  Over the last decades more and more new radioligands have 
been developed, creating a unique insight in the pathophysiology of neuroinflammation, neuronal 
dysfunction, demyelination and remyelination. In this review we will focus on PET-tracers as 
biomarkers for neuroinflammation. 
 IMAGING ACTIVATED MICROGLIA 
The complex and highly dynamic processes of microglia activation is the central characteristic  of 
neuroinflammation and a key element of neurodegeneration in MS.[32,33] Initially, in vivo PET-
studies investigating microglia activation used radioligands that bind to the 18kd-translocator protein 
(TSPO), formerly known as peripheral benzodiazepine receptor. The first successful and now most 
frequently used of the TSPO-radioligands is [11C]PK11195.[34] [11C]PK11195 uptake is increased in 
focal T2 MRI lesions, co-localizes with gadolinium-enhancing T1 lesions in RRMS and is increased in 
normal appearing white and grey matter (NAWM and NAGM) in MS patients compared to healthy 
controls.[35–37] Overall there is significant positive correlation with [11C]PK11195 uptake and 
disease duration, disability score and brain atrophy.[35–38] However, [11C]PK11195 has several 
disadvantages, including limited brain entrance, poor signal-to-noise ratio and labeling with the 
impractically rapid decaying isotope [11C] (t1/2 = 20.33 minutes).[39] This led to the development of a 
wide range of second generation TSPO radioligands, see table 1 for an overview of TSPO PET-studies 
in MS patients. The main disadvantage of these new tracers is a single nucleotide polymorphisms in 
the TSPO gene (rs697) that induces a variation in binding activity for these second generation TSPO 
tracers.[50] Differences in affinity between the high-affinity binding type and the low-affinity binding 
type varies between the different TSPO tracers from a 4-fold to as high as a 50-fold decrease in 
binding.[50] 
Besides the use of different tracers and genetic polymorphism, comparison of TSPO PET studies can 
be challenging due to differences in quantification methods of specific binding, as well as differences 
in patient population, such as subtypes of MS, disease duration, disease severity and age. Recent 
studies have illustrated the relevance of imaging these different subgroups in further understanding 
the pathophysiology of the different disease stages in MS. 
Giannetti et al. recruited eighteen CIS patients for a [11C]PK11195 study.[43*] They demonstrated a 
global increase in [11C]PK11195 uptake in NAWM and deep grey matter compared to healthy controls 
and a further significant increase in those CIS patients with T2 MRI lesions. Furthermore, higher levels 
of uptake was correlated with a development of MS at 2 year interval. This suggests that diffuse 
inflammatory changes in the NAWM in early phases of the disease predispose for WML development 
and subsequently conversion to MS. This would be in line with previous ex vivo immune-
histochemical studies, showing areas of activated microglia without apparent loss of myelin at risk of 
developing into acute inflammatory lesions.[35,51,52]  
Rissanen et al. used the same TSPO-tracer to image not early but chronic disease in the secondary 
progressive MS (SPMS) patients.[41*] First of all they showed an increase in [11C]PK11195 uptake in 
57% of black holes, which has recently been related to a higher degree of clinical disability by 
Giannetti et al.[42*] Moreover, there was significant increase in tracer uptake in the global NAWM 
and in the thalamus in SPMS patients compared to healthy controls. This is in agreement with the 
pathology findings of a more chronic and diffuse low-grade inflammation behind the BBB in the 
progressive phase of the disease.[53] 
In the RRMS there seems to be an association between disease activity and global microglia activity 
measured with TSPO PET. On one hand, Park et al. found no increase in [11C]PBR28 uptake in the 
NAWM of four clinically and radiologically stable RRMS patients.[45*] However, Colasanti et al. 
described a positive relation between [18F]PBR111 uptake and disease severity scores in eleven RRMS 
patients.[46*] 
Overall, increase in TSPO uptake appears to be related to disease severity and progression. 
 
NOVEL PET-TRACERS FOR ACTIVATED MICROGLIA 
Besides TSPO radioligands, new PET-tracers with different binding targets on microglia are under 
development. 
 
In MS the purinergic, adenosine triphosphate (ATP) binding, receptor P2X7 (P2X7R) is upregulated on 
microglia. Binding of ATP to the receptor activates the microglia, which leads to proliferation and 
release of the pro-inflammatory cytokine and subsequently microglia recruitment.[54] Recently, ATP-
dependent release of tumor necrosis factor α (TNFα) was demonstrated to have a neuroprotective 
effect in MS.[55] Moreover, a rare single nucleotide polymorphism rs28360457 in the P2X7R gene 
has been described to protect against the risk of developing MS.[56*] All in all, P2X7R is an 
interesting target for PET-tracers and potentially also for drug development.  A first P2X7R PET-tracer 
[11C]A-740003 is under evaluation in animal models of neuroinflammation by Janssen et al.[57] Gao 
et al. developed a second radioligand [11C]GSK1482160 which has yet to be evaluated in vivo.[58] 
 
Secondly, the adenosine A2Areceptor (A2AR) has been proposed as a new in vivo target for imaging 
neuro-inflammation. In vitro studies show inflammatory stimuli lead to upregulation of A2AR on 
microglial cells and subsequently alter their morphology and behavior.[59] This possibly provides an 
endogenous pathway to limit neuro-inflammation and alter the pathophysiology process of 
neurodegeneration. [60] Rissanen et al. showed an increase uptake of the A2AR PET-tracer 
[11C]TMSX in NAWM of MS patients compared to healthy controls, which was associated with higher 
EDSS and increased brain tissue loss.[61,62] On the downside, [11C]TMSX suffers from low binding 
potentials and high non-specific binding. Therefore, new A2AR tracers are currently under 
investigations.  
 
LABELLING DRUGS THAT TARGET NEUROINFLAMMATION 
Furthermore, PET-tracers have been developed to analyze the organ and tissue distribution of drugs 
currently used in or under development for treatment of MS. As these drugs usually have a long 
pharmacokinetic half-life the long-lived positron emitters [124I] (t1/2 = 4.2 days) and [89Zr] (t1/2 = 3.3 
days) are more commonly used. 
 
To quantify the brain penetration of siponimod (BAF312), a selective sphingosine-1-phosphate 
receptor (S1PR) agonist in phase 3 development for treatment of SPMS, Briard et al. developed 
compound MS565.[63,64] By slightly modifying the structure of BAF312 this molecule can be labelled 
to [124I] for PET imaging. Despite the additional iodine atom the biochemical properties and 
pharmacokinetics of[124I]MS565 remain very close to the original compound. In a similar fashion they 
previously developed [124I]BZM055 as a surrogate tracer to study the biodistribution of fingolimod 
(FTY720), a S1PR agonist approved for the treatment of RRMS.[65] Further validation of these 
radioligands is necessary. 
 
In contrast to radioligands based on MS specific small molecules, radioactive labelling of monoclonal 
antibodies (mAbs) has already been validated in oncology.[66] Similar studies in MS patients can give 
us important insights in the mechanisms responsible for the therapeutic effect of mAbs in MS. A pilot 
study presented at ECTRIMS 2015 suggested that [89Zr]-labelled rituximab, a chimeric monoclonal 
antibody (mAb) against the CD20 molecule on mature B lymphocytes used in the treatment of 
RRMS.[67] There was no evidence of cerebral penetration for rituximab in this pilot study with two 
active RRMS patients, suggesting the (early) therapeutic effects of this drug are independent of CNS 
penetration. Further larger studies with labeled mAbs are highly relevant, especially in light of the 
recently reported phase III result of the ocrelizumab trials in MS.[68] 
 
 
CONCLUSION 
Current advances in MRI and PET techniques have expanded the armamentarium for in vivo 
visualization and quantification of the pleomorphic aspects of neuroinflammation in MS, providing us 
with a unique insight in its pathogenesis, clinical relevance and therapy responsiveness not possible 
with conventional MRI techniques. Further work should aim at validating these novel imaging 
methods and ideally implementing them in the clinical practice and drug development. 
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Figure 1 Leptomeningeal enhancement in MS 
 
Post-contrast sagittal and axial 3D fluid attenuated inversion recovery (FLAIR) images obtained at 3 
Tesla showing focal leptomeningeal enhancement in two relapsing remitting MS patients clinically 
and radiologically stable under (A) interferon beta 1-alpha and (B) glatiramer acetate treatment. 
 
(Original figure) 
 
 
 
Table 1  Overview of in vivo positron emission tomography studies with 18kd-translocator protein 
(TSPO) tracers in multiple sclerosis patients. 
 
CIS = clinically isolated syndrome, EDSS = expanded disability status scale, GM = grey matter, HC = 
healthy control, MS = multiple sclerosis, NAWM = normal appearing white matter, PPMS = primary 
progressive multiple sclerosis, RRMS = relapsing remitting multiple sclerosis, SPMS = secondary 
progressive multiple sclerosis, WM = white matter, WML = white matter lesions 
 
(Original Table) 
  
   
Tabel 1 (original) 
TSPO tracer Subjects Main findings Reference 
[11C]PK11195 2 RRMS Increased [11C]PK11195 uptake in an 
active MS lesion, not in chronic lesions. 
Vowinkel et al. 
1997[34] 
 8 RRMS, 1 
SPMS, 3 
PPMS, 8 HC 
Increased global [11C]PK11195 uptake in 
patients compared to HCs and further 
increase in [11C]PK11195 uptake in 
active and inactive WML. 
Banati et al. 
2000[35] 
 13 RRMS, 7 
SPMS, 2 
PPMS, 7 HC 
Increased [11C]PK11195 uptake in active 
WML, decreased [11C]PK11195 uptake 
in inactive WML. Significantly higher 
[11C]PK11195 uptake in NAWM in PPMS 
compared to RRMS. 
Debruyne et al. 
2003[36] 
 13 RRMS, 7 
SPMS, 2 
PPMS, 8 HC 
Positive correlation between 
[11C]PK11195 uptake in NAWM and 
brain atrophy. Negative correlation 
between [11C]PK11195 uptake in T2 
lesions and brain atrophy. 
Versijpt et al. 
2005[38] 
 10 RRMS, 8 
SPMS, 8 HC 
Cortical [11C]PK11195 uptake is 
increased in MS patients compared to 
HCs and in SPMS compared to RRMS. 
Total cortical [11C]PK11195 uptake 
correlates with EDSS scores, with a 
stronger correlation for the SPMS 
subgroup. 
Politis et al. 
2012[37] 
 9 RRMS Decreased [11C]PK11195 uptake in WM 
and cortical GM after 1 year of 
treatment with glatiramer acetate. 
Ratchford et al. 
2012[40] 
 10 SPMS, 8 
HC 
Increased [11C]PK11195 uptake in 
NAWM and thalamus of patients 
compared to HCs. High [11C]PK11195 
uptake in 57% of chronic T1 lesions in 
patients. 
Rissanen et al. 
2014[41*] 
 10 RRMS, 8 
SPMS, 1 
PPMS 
Positive correlation between 
[11C]PK11195 uptake in black holes and 
EDSS and disease progression in 
SPMS/PPMS subgroup. 
Giannetti et al. 
2014[42*] 
 18 CIS, 8 HC Increased [11C]PK11195 uptake in 
NAWM and central GM of CIS patients 
compared to HCs. Higher [11C]PK11195 
uptake correlates with higher EDSS and 
higher risk of conversion to MS. 
Giannetti et al. 
2015[43*] 
[11C]PBR28 11 MS (mostly 
RRMS), 7 HC 
No difference in global [11C]PBR28 
uptake between patients and HCs. 
Increased [11C]PBR28 uptake in 
gadolinium enhancing WML and 
increased [11C]PBR28 uptake preceding 
gadolinium enhancement. Positive 
correlation between [11C]PBR28 uptake 
and disease duration, but not with 
EDSS. 
Oh et al. 2011[44] 
 4 stable 
RRMS, 4 HCs 
No significant difference in [11C]PBR28 
uptake between patients and HCs. Good 
test-retest reproducibility. 
Park et al. 
2015[45*] 
[18F]PBR111 11 RRMS, 11 
HC 
Increased [18F]PBR111 uptake in WML 
and perilesional WM compared to the 
WM of HCs. Positive correlation 
between [18F]PBR111 uptake and MS 
severity scores in patients. 
Colasanti et al. 
2014[46*] 
[11C]vinpocetine 4 MS (mostly 
RRMS) 
Uptake of [11C]vinpocetine is higher 
than [11C]PK11195 in regions of brain 
damage, but with minimal overlap in 
peak uptake regions. 
Vas et al. 2008[47] 
[18F]FEDAA1106 9 RRMS, 5 HC No difference in overall [18F]FEDAA1106 
uptake between patients and controls. 
Increase in [18F]FEDAA1106 uptake only 
in one active MS lesions. (No 
genotyping performed.) 
Takano et al. 
2013[48] 
[18F]GE-180-001 9 RRMS, 8 HC Slighty increased [18F]GE-180-001 
uptake in whole WM in patients 
compared to HCs. Higher [18F]GE-180-
001 uptake in inactive WML and a 
further increase in gadolinium 
enhancing lesions. (Preliminary data.) 
Trigg et al. 2015[49] 
 
 
